The smoking-cessation drug, reformulated for nasal delivery, could be launched for dry eye, Oyster Point hopes.
The company’s Eysuvis looks set to be approved for dry eye disease, but meeting expectations in this tough market will not be easy.
Axsome hopes to find a niche with its migraine project, AXS-07, while Kala's latest phase III needs to win over the regulators.
One of the biggest drugs of the year, Abbvie’s Jak inhibitor upadacitinib, could get the nod in August.
Aurinia's lead project shows promise in its back-up use of dry eye, but risks distracting the company from a late-stage lupus trial.
A look at the biggest potential drug launches this year reveals a long list of blockbusters from the likes of Alexion and Abbvie. But what impact will the shutdown have?
Another billion dollar quarter for biotech IPOs signals that investor appetite for high-risk offerings is strong.